

To  
The Honorable  
Mr Adonis Georgiadis  
Minister of Health

Chalandri, November 26 2013

**Subject: Clawback for the second semester of 2013**

Dear Minister,

By means of this letter, we would like to express out industry's deepest concern for the course of the pharmaceutical development of EOPYY.

More specifically, according to the information by EOPYY, it is expected that during the second semester of 2013, substantial transgression as regards the target set for the pharmaceutical expenditure, will be noticed. Such transgression takes place, the moment the pharmaceutical companies have already sustained the transgression of Euro 102 mio for the first semester of 2013.

As you can understand, this additional encumbrance of the pharmaceutical companies with the transgression of the second semester of 2013 can in no case be accepted, given that the companies relied on your reassurances that there are enough measures for now, and that there will be no clawback for the said period. Besides, in this context and based on your above rationale, the companies accepted in good faith, to further reduce the annual target for the pharmaceutical expenditure of EOPYY for 2013 from €2.44 bio. That was provided by the MoU to €2.371 bio relying to your commitment.

Dear Minister, pharmaceutical companies cannot operate in a constantly uncertain and unpredictable environment. Taking into account on one hand your commitment for "zero surprises" and on the other hand that the object of the clawback is to cover a small failure amount and is in no case a levied, horizontal measure/poll tax, we kindly request that you abide by your commitment for zero clawback in the second semester of 2013, given that the pharmaceutical companies relied on your relevant reassurances.

Yours sincerely

Konstantinos M. Frouzis  
President

Fotis Mangalousis  
Director General